ensartinib
Showing 1 - 13 of 13
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- Ensartinib
-
Beijing, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022
Non Small Cell Lung Cancer Trial in Beijing (Ensartinib)
Recruiting
- Non Small Cell Lung Cancer
- Ensartinib
-
Beijing, Beijing, China
- +1 more
Aug 17, 2022
NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)
Available
- Non-Small Cell Lung Cancer
- ALK Gene Rearrangement Positive
- Ensartinib
-
Stanford, California
- +3 more
Oct 18, 2022
NSCLC Trial in Tianjin (Ensartinib, Placebo)
Recruiting
- Non-small Cell Lung Cancer
- Ensartinib
- Placebo
-
Tianjin, ChinaTianJin Medical University Cancer Institute & Hospital
Jul 13, 2022
NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Ensartinib
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Aug 4, 2022
Melanoma Trial in United States (Ensartinib, ALKATI by Customized Nanostring Assay)
Active, not recruiting
- Melanoma
- Ensartinib
- ALKATI by Customized Nanostring Assay
-
Middletown, New Jersey
- +3 more
Jan 25, 2022
Solid Tumor, NSCLC Metastatic Trial in Guanzhou (Ensartinib)
Recruiting
- Solid Tumor
- Non-Small Cell Lung Cancer Metastatic
- Ensartinib
-
Guanzhou, Guangdong, ChinaSun yat-sen Univerisity Cancer Center
Nov 22, 2021
NSCLC Trial in Shijiazhuang (Ensartinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- Ensartinib
-
Shijiazhuang, Hebei, ChinaJun Feng Liu
Feb 6, 2022
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +5 more
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 13, 2022
Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial in Puerto
Recruiting
- Malignant Solid Neoplasm
- +26 more
- Ensartinib
- +2 more
-
Birmingham, Alabama
- +121 more
Aug 24, 2022
ALK-POSITIVE NSCLC Trial in Nanjing (Ensartinib)
Unknown status
- ALK-POSITIVE NSCLC
- Ensartinib
-
Nanjing, Jiangsu Provence, ChinaJiangsu Province Hospital Affiliated to Nanjing Madical Universi
Jan 14, 2019
NSCLC, Carcinoma, NSCLC Trial in New York (Ensartinib, Durvalumab)
Completed
- Non-small Cell Lung Cancer
- +2 more
- Ensartinib
- Durvalumab
-
New York, New YorkResearch Facility
Oct 25, 2018
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +44 more
- Biopsy
- +23 more
-
Birmingham, Alabama
- +166 more
Feb 2, 2023